These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 9676021

  • 21. Deferiprone chelation therapy for thalassemia major.
    Galanello R, Campus S.
    Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
    [Abstract] [Full Text] [Related]

  • 22. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
    Jamuar SS, Lai AH, Tan AM, Chan MY, Tan ES, Ng IS.
    J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K, Sivaramakrishnan G.
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [Abstract] [Full Text] [Related]

  • 24. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
    Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM.
    Blood; 1992 May 15; 79(10):2741-8. PubMed ID: 1586721
    [Abstract] [Full Text] [Related]

  • 25. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
    Kolnagou A, Kleanthous M, Kontoghiorghes GJ.
    Hemoglobin; 2011 May 15; 35(3):186-98. PubMed ID: 21599431
    [Abstract] [Full Text] [Related]

  • 26. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 May 15; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 27. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R.
    Haematologica; 2005 Oct 15; 90(10):1309-14. PubMed ID: 16219566
    [Abstract] [Full Text] [Related]

  • 28. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2006 Oct 15; 30(2):219-27. PubMed ID: 16798647
    [Abstract] [Full Text] [Related]

  • 29. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb 15; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 30. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N.
    Hematology; 2007 Dec 15; 12(6):577-85. PubMed ID: 17852442
    [Abstract] [Full Text] [Related]

  • 31. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A, Kleanthous M, Kontoghiorghes GJ.
    Eur J Haematol; 2010 Nov 15; 85(5):430-8. PubMed ID: 20662901
    [Abstract] [Full Text] [Related]

  • 32. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Nov 15; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 33. Combined therapy with deferoxamine and deferiprone.
    Kattamis A.
    Ann N Y Acad Sci; 2005 Nov 15; 1054():175-82. PubMed ID: 16339663
    [Abstract] [Full Text] [Related]

  • 34. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2010 Jun 15; 34(3):204-9. PubMed ID: 20524810
    [Abstract] [Full Text] [Related]

  • 35. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S.
    Am J Hematol; 2013 Apr 15; 88(4):251-60. PubMed ID: 23460233
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
    Cermak J, Jonasova A, Vondrakova J, Walterova L, Hochova I, Siskova M, Neuwirtova R.
    Hemoglobin; 2011 Apr 15; 35(3):217-27. PubMed ID: 21599434
    [Abstract] [Full Text] [Related]

  • 38. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Apr 15; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 39. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
    Huang YC, Chang JS, Wu KH, Peng CT.
    Hemoglobin; 2006 Apr 15; 30(2):229-38. PubMed ID: 16798648
    [Abstract] [Full Text] [Related]

  • 40. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.